Navigation Links
Roche launches antibody test to aid in diagnosis of challenging prostate cancer cases
Date:4/12/2017

TUCSON, Ariz., April 12, 2017 /PRNewswire/ --

  • Prostate cancer accounts for 15 percent of all cancers diagnosed in men3
  • Elevated expression of p504s has become a useful biomarker in the diagnosis of prostate adenocarcinoma1
  • Roche's anti-p504s (SP116) Primary Antibody is an important tool to aid clinicians in making a more accurate diagnosis with a smaller tissue sample

Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis. This antibody has been validated for use in a dual stain with the VENTANA Basal Cell Cocktail (34ßE12+p63) to aid in distinguishing morphologically difficult cases as benign, atypical or cancerous on a single slide. The assay is an in vitro diagnostic (IVD) primary antibody for use on the VENTANA BenchMark IHC/ISH series of automated slide stainers.

Prostate carcinoma dual stained with anti-p504s (SP116) Rabbit Monoclonal Primary Antibody in red, and VENTANA Basal Cell Cocktail (34ßE12+p63) in brown
Prostate carcinoma dual stained with anti-p504s (SP116) Rabbit Monoclonal Primary Antibody in red, and VENTANA Basal Cell Cocktail (34ßE12+p63) in brown

Elevated expression of p504s – also known as a-methylacyl-CoA racemase (AMACR) – has become a useful biomarker in the diagnosis of prostate adenocarcinoma1. When this biomarker is used in a dual stain with the VENTANA Basal Cell Cocktail  (34ßE12+p63) it can reduce the need for multiple slides to make a diagnosis. This can be critical when limited tissue sample is available, as is often the case with prostate biopsies.

"As the second most common cancer in men, prostate cancer is a serious public health concern," said Ann Costello, Head of Roche Tissue Diagnostics. "The anti-p504s (SP116) Primary Antibody is an important tool to aid clinicians in making a more accurate diagnosis with a smaller tissue sample."

An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, accounting for 15 percent of all cancers diagnosed in men3. The anti-p504s (SP116) Rabbit Monoclonal Primary Antibody enhances the Roche prostate portfolio of key assays used to diagnose prostate cancer.

____________________________________
1
Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am. J. Surg. Pathol. 2001;25:1397-1404.
2 This antibody is intended for in vitro diagnostic (IVD) use. This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information and proper controls.
3 Globocan. Cancer Fact Sheets: Prostate Cancer. Globocan website. http://globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp

About the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody
Anti-p504s (SP116) Rabbit Monoclonal Primary Antibody is intended for laboratory use in the detection of a-methylacyl-CoA racemase (AMACR) in sections of formalin-fixed, paraffin-embedded (FFPE) tissue. This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information and proper controls. This antibody is intended for in vitro diagnostic (IVD) use.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

VENTANA and BENCHMARK are trademarks of Roche. Other product names and trademarks are the property of their respective owners.

Roche Tissue Diagnostics Media Relations
Gabrielle Fimbres
Senior Manager, External Communications
Phone: +1 520.222.4573
Email: gabrielle.fimbres@roche.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/roche-launches-antibody-test-to-aid-in-diagnosis-of-challenging-prostate-cancer-cases-300438414.html


'/>"/>
SOURCE Roche
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Liquidity Services, Inc. Selected by Hoffmann-La Roche Inc. as Sales Channel for Surplus Assets
2. Novira Therapeutics Expands Management Team with Appointment of Klaus Klumpp, Ph.D., the Former Global Head of Roches Virology Discovery Initiatives, as Vice President Discovery Research
3. Platine Pharma Services et Indicia Biotechnology se rapprochent pour renforcer leur leadership en immunomonitoring
4. Cree, Intuitive Surgical, Alexion Pharmaceuticals, Roche and Onyx Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
5. Rochester Medical Announces Third Quarter 2013 Earnings Conference Call Tuesday, July 30, 2013
6. Roche unveils intelligent automation management solution at 2013 Clinical Lab Expo
7. Regenerons Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentechs Lucentis
8. Roche/Chugais Bitopertin Will Garner Nearly $1.5 Billion in Major-Market Sales in 2022 as the First Approved Treatment for Negative Symptoms in Schizophrenia
9. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
10. Rochester Medical to be Acquired by C. R. Bard for Approximately $262 Million
11. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun a ... to its Welch Allyn campus. The ... more than 100 new jobs to Central ... a significant presence for more than 100 years. Hill-Rom,s ... large portion of which will be R&D and engineering ...
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... and big data solutions, today announced that it is ... and STI Technologies Limited to lower diabetes healthcare costs ... STI,s innoviCares card, which is available throughout all provinces ... customers will be eligible for additional savings when shopping ...
(Date:5/3/2017)... N.J. , May 3, 2017  Getinge, ... that contribute to quality enhancement and cost efficiency ... from a study of contemporary practice demonstrating that ... first-line therapy for critically ill patients. The single-center, ... Company,s newer large volume MEGA ® 50cc ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career Step company, ... Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The free webinar, ... be presented by Captain Rommie Duckworth, LP, a career fire captain as well as ...
(Date:5/24/2017)... ... ... Rob Lowe is a sought after actor, and also serves as the host ... topics from all aspects of life, and a new segment is being developed on ... , Podiatry is essential to people’s overall well-being, and if viewers have feet problems, ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dymedix® Diagnostics, Inc., ... today it had completed the first phase of building a global distribution network. ... of world (ROW) authorized dealers specializing in polysomnography accessories. The company plans ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... the pharmaceutical and medical device sectors, today announced the winners of its 3rd ... Entrepreneurs) represent the most influential people in the healthcare industry today. , Out ...
(Date:5/23/2017)... ... May 23, 2017 , ... The National Council on ... to announce the organization’s Certified Strength Coach credential has earned accreditation from the ... program validates the competency of qualified candidates for jobs in the Strength and ...
Breaking Medicine News(10 mins):